PD-L1 Promotes Tumor Growth and Progression by Activating WIP and β-Catenin Signaling Pathways and Predicts Poor Prognosis in Lung Cancer

Scientists showed that PD-L1 regulated lung cancer growth and progression by targeting the WIP and β-catenin signaling. Overexpression of PD-L1 promoted tumor cell growth, migration and invasion in lung cancer cells, whereas PD-L1 knockdown had the opposite effects.
[Cell Death & Disease]
Full Article

Continue reading “PD-L1 Promotes Tumor Growth and Progression by Activating WIP and β-Catenin Signaling Pathways and Predicts Poor Prognosis in Lung Cancer”

Bookmark

No account yet? Register

0
Share

Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib plus Atezolizumab in Metastatic Non-Small Cell Lung Cancer and Metastatic Castration-Resistant Prostate Cancer

Ipsen announced it will join the Exelixis and Roche clinical collaboration and participate in the funding of the recently initiated CONTACT-01 and CONTACT-02 global Phase III pivotal trials.
[Ipsen Pharma]
Ipsen joins clinical collaboration to evaluate cabozantinib (CABOMETYX®) plus atezolizumab in metastatic non-small cell lung cancer and metastatic castration-resistant prostate cancer. (n.d.). Ipsen. Retrieved July 2, 2020, from https://www.ipsen.com/press-releases/ipsen-joins-clinical-collaboration-to-evaluate-cabozantinib-cabometyx-plus-atezolizumab-in-metastatic-non-small-cell-lung-cancer-and-metastatic-castration-resistant-prostate-cancer/ Cite
Press Release

Continue reading “Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib plus Atezolizumab in Metastatic Non-Small Cell Lung Cancer and Metastatic Castration-Resistant Prostate Cancer”

Bookmark

No account yet? Register

0
Share

MicroRNA and ROS Crosstalk in Cardiac and Pulmonary Diseases

The authors focus on the complex crosstalk between miRNAs and ROS in diseases of the cardiac and pulmonary compartments.
[International Journal of Molecular Sciences]
Full Article

Continue reading “MicroRNA and ROS Crosstalk in Cardiac and Pulmonary Diseases”

Bookmark

No account yet? Register

0
Share

Achilles Therapeutics Doses First Patient in Phase I/II Study in Advanced Non-Small Cell Lung Cancer

Achilles Therapeutics announced that it has dosed the first patient in a Phase I/II CHIRON study of a clonal neoantigen T cell therapy in patients with advanced non-small cell lung cancer.
[Achilles Therapeutics (GlobeNewswire, Inc.)]
Press Release

Continue reading “Achilles Therapeutics Doses First Patient in Phase I/II Study in Advanced Non-Small Cell Lung Cancer”

Bookmark

No account yet? Register

0
Share

NMPA Accepts Bio-Thera Solutions’ Biologics License Application (BLA) for BAT1706, A Proposed Biosimilar to Avastin®

Bio-Thera Solutions announced that the China National Medical Products Administration (NMPA) has accepted the Biologics License Application for BAT1706, a proposed biosimilar to Avastin®.
[Bio-Thera Solutions (Business Wire, Inc.)]
Press Release

Continue reading “NMPA Accepts Bio-Thera Solutions’ Biologics License Application (BLA) for BAT1706, A Proposed Biosimilar to Avastin®

Bookmark

No account yet? Register

0
Share
Share